PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers, announced today that Cuong Do, a longtime industry veteran has joined the Seneca Therapeutics Advisory Board. Mr. Do is also an investor in Seneca Therapeutics.
“We are pleased that Cuong has agreed to serve on our Advisory Board,” said James Hussey, CEO of Seneca Therapeutics. “His insights on the development of SVV Armed Constructs and the SVV Gene Library have been particularly helpful. We look forward to working together in the future.”
“I am pleased to join the Seneca Advisory Board,” said Mr. Do. “The company has incredibly interesting technology. I am looking forward to the upcoming clinical study with SVV-001 and Checkpoint inhibitors in the treatment of neuroendocrine tumors and neuroendocrine carcinoma. I am also excited about the expanding platform for SVV-001 Armed Constructs and SVV Gene Library.”
About Seneca Therapeutics
Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.
Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.
